This website uses cookies. By using this website, you agree to our Cookie Policy.
Oct 17, 2014
“Any knock-on effect from the AbbVie board's recommendation against the Shire deal should be limited to other deals similarly structured to access offshore cash and extensively restructure offshore holdings. Many transactions that would not depend on these tax-planning techniques are still good candidates for an inversion.”
- Linda Z. Swartz, Chair of the Tax group at Cadwalader, commenting in Law360 on the effect of the Treasury’s new anti-inversion rules on pending and future inversion transactions.
Scott Cammarn, Mark Chorazak, Jonathan Watkins,Chris Gavin, Joseph Beach, Peter Morreale
Richard Brand, Stephen Fraidin, Jonathan Watkins, James Fee
Michele Maman, Thomas Curtin, Anthony De Leo, Donny Ariel
Nick Shiren and Daniel Tobias will be speaking at this key industry event on April 2 in London.